Synlogic enters research collaboration with roche for development of novel therapy to treat inflammatory bowel disease

Cambridge, mass., june 17, 2021 /prnewswire/ -- synlogic, inc. (nasdaq: sybx), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today that it has entered into a research collaboration agreement with roche for the discovery of a novel synthetic biotic™ medicine for the treatment of inflammatory bowel disease (ibd).
SYBX Ratings Summary
SYBX Quant Ranking